Anti-angiogenic therapy can induce tumor hypoxia, and pathways upregulated in the setting of tumor hypoxia, such as sphingosine phosphate and c-Met/HGF signaling, also contribute to TKI resistance24–26. This evidence concerns the gene HGF and neoplasm.